Company intelligence / Profile preview

Prolight Diagnostics

Stockholm, Sweden

Ownership: Private
Employees: ~16
Development stage: Other

Overview

The company has demonstrated proof-of-performance results measuring thyroid stimulating hormone (TSH) levels in human plasma samples in November 2022 and troponin in serum samples in June 2023, achieving protein concentration measurements down to single-digit nanograms per litre with laboratory-grade reproducibility

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

The Technology Partnership

Beyond the preview

Go deeper on Prolight Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolight Diagnostics.

Explore the full profile